Publication Date: October 5, 2025
Researchers at City of Hope Medical Center, in collaboration with the National Cancer Institute (NCI), have announced their ambitious initiative to investigate the combined impact of metabolic interventions on cardiometabolic health in prostate cancer patients undergoing androgen deprivation therapy (ADT). The study, titled “IMPACT-ADT Trial,” aims to examine the integration of time-restricted eating, GLP1 receptor agonists, and heart-healthy diets to reduce cardiovascular risks during cancer treatment.
In this article:
What changed?
The IMPACT-ADT Trial signals a progressive shift in prostate cancer care by addressing cardiometabolic challenges that arise during ADT. While ADT remains vital in controlling prostate carcinoma, it is associated with adverse metabolic effects, including increased risk of cardiovascular disease. This trial emphasizes proactive, multidisciplinary interventions that could reshape patient outcomes and standard-of-care practices.
What are the trial objectives?
Key goals and scope
The trial seeks to evaluate how synergistic metabolic interventions—like time-restricted eating, GLP1 receptor agonists (e.g., semaglutide and tirzepatide), and tailored nutritional plans—can mitigate cardiovascular and metabolic risks in prostate cancer patients. Researchers will assess biomarkers, cardiovascular imaging, electronic health records, and clinical questionnaires to collect robust evidence.
Conditions under investigation
- Prostate carcinoma
- Recurrent prostate carcinoma
The study specifically targets individuals undergoing ADT, a therapy often linked to compromised heart health and metabolic imbalance.
How will the study be conducted?
Multi-modal interventions
The study integrates comprehensive methods: administering medications (e.g., semaglutide), implementing short-term fasting protocols, and offering lifestyle counseling via internet-based platforms. Investigators will also implement tools like biospecimen collection and cardiac imaging technologies.
Study timeline and recruitment
The clinical trial remains not yet recruiting as of October 2025, according to the latest updates from ClinicalTrials.gov. Recruitment announcements are expected soon.
Who should care?
This trial has implications for clinical, regulatory, and quality teams in the oncology sector. Medical device manufacturers, pharmaceutical companies, and nutritional intervention specialists should monitor its outcomes for potential industry-wide applications. Additionally, policymakers may gain insights into crafting cancer care guidelines that incorporate preventive cardiometabolic strategies.
FAQ
-
What is time-restricted eating? Time-restricted eating limits food intake to specific windows during the day, potentially improving metabolic health.
-
What are GLP1 receptor agonists? GLP1 receptor agonists, such as semaglutide and tirzepatide, are medications that enhance glucose regulation and support weight management.
-
When will the study begin recruiting? Recruitment is not yet open. Updates will likely follow soon.
-
Why focus on cardiometabolic health for prostate cancer patients? ADT can increase cardiovascular risks and metabolic disturbances, warranting preventative care approaches.
Conclusion
The IMPACT-ADT Trial represents a transformative effort toward integrating cardiometabolic interventions with prostate cancer care. Regulators and industry stakeholders should remain informed to leverage findings that may redefine cancer treatment paradigms.
Disclaimer
The information provided herein is for professional purposes only and does not constitute legal or medical advice.
Full Announcement
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07202247?term=medical+device